

# Treatment of COVID 19

## NIH guidelines

Najwa Khuri-Bulos MD, FIDSA

Figure 2. Therapeutic Management of Hospitalized Adults With COVID-19 Based on Disease Severity

DISEASE SEVERITY	PANEL'S RECOMMENDATIONS
<b>Hospitalized but Does Not Require Supplemental Oxygen</b>	<p>The Panel <b>recommends against</b> the use of <b>dexamethasone (AIIa)</b> or <b>other corticosteroids (AIII)</b>.<sup>a</sup></p> <p>There is insufficient evidence to recommend either for or against the routine use of remdesivir. For patients at high risk of disease progression, remdesivir may be appropriate.</p>
<b>Hospitalized and Requires Supplemental Oxygen</b>	<p>Use one of the following options:</p> <ul style="list-style-type: none"><li>• <b>Remdesivir<sup>b</sup></b> (e.g., for patients who require minimal supplemental oxygen) <b>(BIIa)</b></li><li>• <b>Dexamethasone plus remdesivir<sup>b</sup></b> (e.g., for patients who require increasing amounts of supplemental oxygen) <b>(BIII)</b></li><li>• <b>Dexamethasone</b> (when combination with remdesivir cannot be used or is not available) <b>(BI)</b></li></ul>
<b>Hospitalized and Requires Oxygen Delivery Through a High-Flow Device or Noninvasive Ventilation</b>	<p>Use one of the following options:</p> <ul style="list-style-type: none"><li>• <b>Dexamethasone (AI)</b></li><li>• <b>Dexamethasone plus remdesivir<sup>b</sup> (BIII)</b></li></ul> <p>For recently hospitalized<sup>c</sup> patients with rapidly increasing oxygen needs and systemic inflammation:</p> <ul style="list-style-type: none"><li>• Add either <b>baricitinib (BIIa)</b> or <b>IV tocilizumab (BIIa)</b> to one of the two options above<sup>d</sup></li><li>• If neither baricitinib nor IV tocilizumab is available or feasible to use, <b>tofacitinib</b> can be used instead of baricitinib <b>(BIIa)</b> or <b>IV sarilumab</b> can be used instead of IV tocilizumab <b>(BIIa)</b>.</li></ul>
<b>Hospitalized and Requires IMV or ECMO</b>	<ul style="list-style-type: none"><li>• <b>Dexamethasone (AI)</b></li></ul> <p>For patients who are within 24 hours of admission to the ICU:</p> <ul style="list-style-type: none"><li>• <b>Dexamethasone plus IV tocilizumab (BIIa)</b></li><li>• If IV tocilizumab is not available or not feasible to use, <b>IV sarilumab</b> can be used <b>(BIIa)</b>.</li></ul>

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion

COVID 19 recent guidelines  
Note the use of remdisivir for patients who are hospitalized and In need of oxygen

Note also use of tocilizumab is Recommended when progression Occurs and can be combined with Steroids for patients who are Very sick